TRIV-573 for Atopic Dermatitis
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.
Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo).
The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.
Are You a Good Fit for This Trial?
This trial is for adults who have moderate to severe, active atopic dermatitis (also known as eczema).Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- TRIV-573
Trial Overview
The study is testing a new medication called TRIV-573 compared to a placebo (inactive treatment) in adults with moderate to severe atopic dermatitis. Participants are randomly assigned and will receive five doses over about 40 weeks.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
Triveni Bio
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.